Posts found in:
Brad L. Schoenfeld
How Emerging Companies Can Negotiate Better Life Sciences Commercial Contracts
- Brad L. Schoenfeld
- |
- January 9, 2020
Most life sciences companies negotiate numerous commercial contracts each year and must rely on big industry players for essential testing, supply and manufacturing partnerships. But these relationships can feel very unbalanced because large vendors seem to have far more negotiating power than any emerging company. Less favorable terms can have…
Why Emerging Life Science And Pharma Companies Should Apply The CRO Model To Commercial Contracts
- Brad L. Schoenfeld
- |
- February 19, 2019
2019 is off to a fast start in the life science, pharmaceutical and medical device industries with unprecedented market growth. Life sciences, in particular, continue on an upward trend, accounting for nearly 15 percent of venture deal flow in 2018, more than 60 percent of which were deals of $50…
